RARalpha Inhibitors
10 drugsAbout RARalpha
RARalpha, or Retinoic Acid Receptor alpha, is a nuclear receptor that regulates gene expression as a ligand-activated transcription factor. It influences cellular processes, making it a drug development target.
RARalpha's involvement in cellular differentiation and proliferation has led to the development of several FDA-approved drugs. Currently, there is no genetic evidence directly linking RARalpha to specific diseases.
Four FDA-approved drugs target RARalpha, including topical treatments like RETIN-A, ALTRENO, TWYNEO and ATRALIN. All four drugs are small molecules.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA with only 1 trials.
Top RARalpha Drugs
Three companies have approved drugs targeting RARalpha.
The competitive landscape is moderately concentrated, suggesting moderate entry barriers.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| RETIN-A | VALEANT PHARMS NORTH | 1971 | 1 |
| ARAZLO | BAUSCH | 2019 | 1 |
| TWYNEO | MAYNE PHARMA INC | 2021 | 1 |
| ATRALIN | DOW PHARM | 2007 | 1 |
| FABIOR | MAYNE PHARMA INC | 2012 | 1 |
| ALTRENO | DOW PHARM | 2018 | 1 |
| PANRETIN | ADVANZ PHARMA | 1999 | 1 |
RARalpha Drug Modality Landscape
Modalities
Routes of Administration
RARalpha is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies could provide differentiation.
RARalpha Clinical Trials 113 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 27 | 24 | 1 | 2 | 96% |
| Phase 2 | 21 | 15 | 0 | 5 | 100% |
| Phase 3 | 27 | 23 | 2 | 2 | 92% |
| Phase 4 | 38 | 33 | 5 | 0 | 87% |
Top Sponsors
By Modality
RARalpha Drug Approval Timeline (1971 - 2021)
The first drug was approved in 1971, and the most recent in 2021.
The 51-year approval span indicates a mature but not saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 10 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 10-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 85 clinical trials targeting RARalpha.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities